JP2017507181A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507181A5
JP2017507181A5 JP2016570199A JP2016570199A JP2017507181A5 JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5 JP 2016570199 A JP2016570199 A JP 2016570199A JP 2016570199 A JP2016570199 A JP 2016570199A JP 2017507181 A5 JP2017507181 A5 JP 2017507181A5
Authority
JP
Japan
Prior art keywords
seq
protein
uspa2
immunogenic composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016570199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507181A (ja
JP6585085B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/051308 external-priority patent/WO2015125118A1/en
Publication of JP2017507181A publication Critical patent/JP2017507181A/ja
Publication of JP2017507181A5 publication Critical patent/JP2017507181A5/ja
Application granted granted Critical
Publication of JP6585085B2 publication Critical patent/JP6585085B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016570199A 2014-02-24 2015-02-20 Uspa2タンパク質構築物およびそれらの使用 Expired - Fee Related JP6585085B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US61/943,909 2014-02-24
US201461946932P 2014-03-03 2014-03-03
US201461946937P 2014-03-03 2014-03-03
US61/946,932 2014-03-03
US61/946,937 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2017507181A JP2017507181A (ja) 2017-03-16
JP2017507181A5 true JP2017507181A5 (cg-RX-API-DMAC7.html) 2018-04-05
JP6585085B2 JP6585085B2 (ja) 2019-10-02

Family

ID=52629643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570199A Expired - Fee Related JP6585085B2 (ja) 2014-02-24 2015-02-20 Uspa2タンパク質構築物およびそれらの使用

Country Status (28)

Country Link
US (3) US10040832B2 (cg-RX-API-DMAC7.html)
EP (2) EP3498292B1 (cg-RX-API-DMAC7.html)
JP (1) JP6585085B2 (cg-RX-API-DMAC7.html)
KR (1) KR102515835B1 (cg-RX-API-DMAC7.html)
CN (2) CN111499701A (cg-RX-API-DMAC7.html)
AU (1) AU2015220369B2 (cg-RX-API-DMAC7.html)
BE (1) BE1022345A9 (cg-RX-API-DMAC7.html)
BR (1) BR112016019525B1 (cg-RX-API-DMAC7.html)
CA (1) CA2939862C (cg-RX-API-DMAC7.html)
CY (2) CY1121535T1 (cg-RX-API-DMAC7.html)
DK (2) DK3110438T3 (cg-RX-API-DMAC7.html)
EA (1) EA034352B1 (cg-RX-API-DMAC7.html)
ES (2) ES2899300T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20190412T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057505T2 (cg-RX-API-DMAC7.html)
IL (1) IL246994B (cg-RX-API-DMAC7.html)
LT (2) LT3498292T (cg-RX-API-DMAC7.html)
ME (1) ME03335B (cg-RX-API-DMAC7.html)
MX (1) MX376079B (cg-RX-API-DMAC7.html)
PL (2) PL3110438T3 (cg-RX-API-DMAC7.html)
PT (2) PT3498292T (cg-RX-API-DMAC7.html)
RS (2) RS62592B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606272PA (cg-RX-API-DMAC7.html)
SI (2) SI3110438T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100728T1 (cg-RX-API-DMAC7.html)
TW (1) TW201620927A (cg-RX-API-DMAC7.html)
UY (1) UY36006A (cg-RX-API-DMAC7.html)
WO (1) WO2015125118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
WO2020039033A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
JP2022543281A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2274495C (en) * 1996-12-20 2009-06-02 Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CA2452836C (en) * 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
CN101243104B (zh) * 2005-08-10 2012-07-18 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用
JP5269594B2 (ja) * 2005-08-10 2013-08-21 アルネ・フオシユグレン・アー・ベー モラクセラ・カタラーリスと上皮細胞、細胞外マトリックス蛋白質及び補体系の相互作用
ZA200805602B (en) * 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20140286977A1 (en) * 2011-05-11 2014-09-25 Riesbeck Healthcare Sweden Ab Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Similar Documents

Publication Publication Date Title
JP2017507181A5 (cg-RX-API-DMAC7.html)
JP2016509011A5 (cg-RX-API-DMAC7.html)
JP2012126742A5 (cg-RX-API-DMAC7.html)
JP2016512425A5 (cg-RX-API-DMAC7.html)
JP2008538183A5 (cg-RX-API-DMAC7.html)
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
CN106659777A8 (zh) 免疫原性组合产品
HRP20200466T1 (hr) Fuzijski proteini i kombinacijska cjepiva
HRP20211926T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
JP2017048194A5 (cg-RX-API-DMAC7.html)
JP2013543499A5 (cg-RX-API-DMAC7.html)
JP2012115277A5 (cg-RX-API-DMAC7.html)
IL276210B2 (en) Mers-cov vaccine
JP2008525033A5 (cg-RX-API-DMAC7.html)
JP2010273685A5 (cg-RX-API-DMAC7.html)
JP2013172734A5 (cg-RX-API-DMAC7.html)
JP2012095652A5 (cg-RX-API-DMAC7.html)
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
JP2013539454A5 (cg-RX-API-DMAC7.html)
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2016514713A5 (cg-RX-API-DMAC7.html)
JP2015533791A5 (cg-RX-API-DMAC7.html)
JP2016508503A5 (cg-RX-API-DMAC7.html)
WO2011094357A3 (en) Repiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
JP2015536312A5 (cg-RX-API-DMAC7.html)